

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

PAR PHARMACEUTICAL, INC., WOCKHARDT BIO AG, and
AMNEAL PHARMACEUTICALS LLC,
Petitioners,

v.

JAZZ PHARMACEUTICALS, INC.,
Patent Owner.

Case IPR2015-00551¹
Patent 8,457,988

**PETITIONER'S MOTION TO WITHDRAW COUNSEL AND
SUBSTITUTE NEW COUNSEL**

Mail Stop "PATENT BOARD"

Patent Trial and Appeal Board
U.S. Patent and Trademark Office
P.O. Box 1450
Alexandria, VA 22313-1450

¹ Cases IPR2015-01814 and IPR2015-01817 have been joined with this proceeding.

Petitioner's Motion to Withdraw Counsel and Substitute New Counsel**I. RELIEF REQUESTED**

Under 37 C.F.R. § 42.10(e), counsel for Petitioner Par Pharmaceutical, Inc. requests that the Board authorize withdrawal of counsel and substitution of new counsel. Patent Owner has not stated it opposes this motion.

II. STATEMENT OF FACTS SHOWING GOOD CAUSE FOR THE BOARD TO AUTHORIZE WITHDRAWAL OF COUNSEL

Petitioner Par Pharmaceutical, Inc. wishes to withdraw Aziz Burgy as Lead Counsel, substitute new Lead Counsel and add additional Backup Counsel in the above-captioned *inter partes* review proceeding. Specifically, Petitioner intends to appoint:

Lead Counsel	Backup Counsel
Janine A. Carlan (Reg. No. 42,387) Arent Fox LLP 1717 K Street NW Washington, DC 20006 (202) 857-6000 janine.carlan@arentfox.com	Richard J. Berman (Reg. No. 39,107) Arent Fox LLP 1717 K Street NW Washington, DC 20006 (202) 857-6000 richard.berman@arentfox.com
	Bradford C. Frese (Reg. No. 69,772) Arent Fox LLP 1717 K Street NW Washington, DC 20006 (202) 857-6000 bradford.frese@arentfox.com

Petitioner's new Lead Counsel and Backup Counsel meet the requirements of 37 C.F.R. § 42.10(c) and are registered practitioners. In addition, Petitioner's new counsel has read and intends to comply with the Office Patent Trial Practice

IPR2015-00551
Patent No. 8,457,988

Petitioner's Motion to Withdraw Counsel and Substitute New Counsel


Guide and the Board's Rules of Practice for Trials, as set forth in Part 42 of the C.F.R.

An executed Power of Attorney as authorized in the Notice of Filing Date Accorded (Paper 4) is being filed concurrently.

A decision on whether to institute this *inter partes* review has already been issued, and no extensions of time will be needed upon grant of this Motion. Furthermore, it is believed that this Motion will not hinder the economy, the integrity of the patent system, the efficiency of the Office, or the ability of the Office to timely complete this proceeding. *See* 35 U.S.C. § 316(b).

Thus, Petitioner Par Pharmaceutical, Inc. respectfully requests that the Board grant this motion to withdraw counsel and substitute new counsel. Updated Mandatory Notices Under 37 C.F.R. §42.8(b)(3) and (b)(4) will be filed upon grant of the present motion.

Date: January 20, 2016
ARENT FOX LLP
1717 K Street, NW
Washington, DC 20006
202.857.6000

Respectfully Submitted,

Bradford C. Frese
Registration No. 69,772
Attorney for Petitioner
Par Pharmaceutical, Inc.

CERTIFICATION OF SERVICE (37 C.F.R. §§ 42.6(e), 42.105(a))


The undersigned hereby certifies that the above-captioned “Petitioner’s Motion to Withdraw Counsel and Substitute New Counsel” was served in its entirety on January 20, 2016, upon the following parties via Electronic Mail:

F. Dominic Cerrito
QUINN EMANUEL URQUHART &
SULLIVAN LLP
51 Madison Avenue
22nd Floor
New York, NY 10010
NickCerrito@quinnemanuel.com

John V. Biernacki
Jones Day
North Point
901 Lakeside Avenue
Cleveland, OH 44114
JVBiernacki@JonesDay.Com

Date: January 20, 2016
ARENT FOX LLP
1717 K Street, NW
Washington, DC 20006
202.857.6000

Respectfully Submitted,



Bradford C. Frese
Registration No. 69,772
Attorney for Petitioner
Par Pharmaceutical, Inc.